| Characteristics |
Pre ART No (%) |
HAART No (%) |
Total No (%) |
Functional Status B
Working
Ambulatory & Bedridden |
223 (96.1)
9 (3.9) |
213 (91.8)
19 (8.2) |
436 (94)
28 (6) |
WHO Stage B
Stage I
Stage II
Stage III
Stage IV |
181 (78)
42 (18.1)
9 (3.9)
0 (0) |
134 (57.8)
32 (13.8)
56 (24.1)
10 (4.3) |
315 (67.9)
74 (16)
65 (14)
10 (2.1) |
Hemoglobin level B
<10mg/dl
≥10mg/dl |
12 (5.2)
220 (94.8) |
24 (10.3)
208 (89.7) |
36 (7.8)
428 (92.2) |
CD4+ Count B
<200
200-349
350-499
>=500 |
0 (0)
14 (6)
93 (40)
125 (54) |
107 (46.1)
116 (50)
8 (3.5)
1 (0.4) |
107 (23)
130 (28)
101 (21.8)
126 (27.2) |
Substance use B
Yes
No |
24 (10.3)
208 (89.7) |
58 (25)
174 (75) |
82 (17.7)
382 (82.3) |
Prophylaxis B
Yes
No |
62 (26.7)
170 (73.3) |
206 (88.8)
26 (11.2) |
268 (57.8)
196 (42.2) |
CD4+ Count F
<200
200-349
350-499
>=500 |
20 (8.6)
62 (26.7)
68 (29.3)
82 (35.4) |
13 (5.6)
71 (30.6)
76 (32.8)
72 (31) |
33 (7.1)
133 (28.7)
144 (31)
154 (33.2) |
Substance use F
Yes
No |
25 (10.8)
207 (89.2) |
55 (23.7)
177 (76.3) |
70 (17.2)
384 (82.8) |
Prophylaxis F
Yes
No |
95 (40.9)
137 (59.1) |
98 (42.2)
134 (57.8) |
193 (41.6)
271 (58.4) |
Functional Status F
Working
Ambulatory & Bedridden |
186 (90.2)
46 (19.8) |
230 (99.1)
2 (0.9) |
466 (89.7)
48 (10.3) |
F =follow up, B= baseline